Down 35% in the last 12 months, the market has clearly been skeptical of biotech company Dendreon . Concerns over the market opportunity for its prostate cancer drug, Provenge, and question marks over its ability to become profitable have pressured the stock over the last few months. Yesterday, however, the company received approval to market its therapeutic in the EU, and shares were up 5% by the market close. Is this approval the boost that Dendreon needs, or are there other struggles ahead that investors need to consider? What about competition from drugs made by Johnson & Johnson and Medivation ? Analysts David Williamson and Max Macaluso discuss these topics in the following video segment.
More compelling stock ideas
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The relevant video segment can be found between 0:00 and 4:16.
The article A Big Boost or False Hope For This Biotech? originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.